American Fork Dialysis Center is a medicare approved dialysis facility center in American Fork, Utah and it has 8 dialysis stations. It is located in Utah county at 1159 East 200 North Ste 150, American Fork, UT, 84003. You can reach out to the office of American Fork Dialysis Center at (801) 763-0652. This dialysis clinic is managed and/or owned by University Of Utah Dialysis Program. American Fork Dialysis Center has the following ownership type - Non-Profit. It was first certified by medicare in August, 2007. The medicare id for this facility is 462534 and it accepts patients under medicare ESRD program.
| Name | American Fork Dialysis Center |
|---|---|
| Location | 1159 East 200 North Ste 150, American Fork, Utah |
| No. of Dialysis Stations | 8 |
| Medicare ID | 462534 |
| Managed By | University Of Utah Dialysis Program |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 1159 East 200 North Ste 150, American Fork, Utah, 84003 | |
| (801) 763-0652 | |
News Archive
A team of scientists from the University of California, Los Angeles, USA, recently conducted a survey investigating the association between availability of testing facilities and COVID-19-related behavioral aspects. Their findings reveal that testing unavailability independently influences certain COVID-19-related behaviors that may increase the risk of SARS-CoV-2 transmission.
SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.
Dey Pharma, L.P., a subsidiary of Mylan Inc., today launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use.
The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and well over 282,000 deaths. A new study published on the preprint server bioRxiv in May 2020 suggests that the long-term impact of the virus could include activation of dormant bacterial infections like tuberculosis (TB).
Motor vehicle crashes rank as the leading cause of teen deaths and in 2008, 16% of all distraction-related fatal automobile crashes involved drivers under 20 years of age.
› Verified 6 days ago
| NPI Number | 1316037971 |
| Organization Name | University Of Utah |
| Doing Business As | American Fork Dialysis Center |
| Address | 120 N 1220 E Ste 14 American Fork, Utah, 84003 |
| Phone Number | (801) 581-8573 |
News Archive
A team of scientists from the University of California, Los Angeles, USA, recently conducted a survey investigating the association between availability of testing facilities and COVID-19-related behavioral aspects. Their findings reveal that testing unavailability independently influences certain COVID-19-related behaviors that may increase the risk of SARS-CoV-2 transmission.
SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.
Dey Pharma, L.P., a subsidiary of Mylan Inc., today launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use.
The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and well over 282,000 deaths. A new study published on the preprint server bioRxiv in May 2020 suggests that the long-term impact of the virus could include activation of dormant bacterial infections like tuberculosis (TB).
Motor vehicle crashes rank as the leading cause of teen deaths and in 2008, 16% of all distraction-related fatal automobile crashes involved drivers under 20 years of age.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 9 |
News Archive
A team of scientists from the University of California, Los Angeles, USA, recently conducted a survey investigating the association between availability of testing facilities and COVID-19-related behavioral aspects. Their findings reveal that testing unavailability independently influences certain COVID-19-related behaviors that may increase the risk of SARS-CoV-2 transmission.
SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.
Dey Pharma, L.P., a subsidiary of Mylan Inc., today launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use.
The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and well over 282,000 deaths. A new study published on the preprint server bioRxiv in May 2020 suggests that the long-term impact of the virus could include activation of dormant bacterial infections like tuberculosis (TB).
Motor vehicle crashes rank as the leading cause of teen deaths and in 2008, 16% of all distraction-related fatal automobile crashes involved drivers under 20 years of age.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 24 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 159 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
A team of scientists from the University of California, Los Angeles, USA, recently conducted a survey investigating the association between availability of testing facilities and COVID-19-related behavioral aspects. Their findings reveal that testing unavailability independently influences certain COVID-19-related behaviors that may increase the risk of SARS-CoV-2 transmission.
SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.
Dey Pharma, L.P., a subsidiary of Mylan Inc., today launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use.
The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and well over 282,000 deaths. A new study published on the preprint server bioRxiv in May 2020 suggests that the long-term impact of the virus could include activation of dormant bacterial infections like tuberculosis (TB).
Motor vehicle crashes rank as the leading cause of teen deaths and in 2008, 16% of all distraction-related fatal automobile crashes involved drivers under 20 years of age.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at American Fork Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 25 |
| Hypercalcemia patient months | 171 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 6 |
| Patients with Serumphosphor | 26 |
| Patients with Serumphosphor less than 3.5 mg/dL | 1 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 27 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 28 |
| Patients with Serumphosphor greater than 7 mg/dL | 17 |
News Archive
A team of scientists from the University of California, Los Angeles, USA, recently conducted a survey investigating the association between availability of testing facilities and COVID-19-related behavioral aspects. Their findings reveal that testing unavailability independently influences certain COVID-19-related behaviors that may increase the risk of SARS-CoV-2 transmission.
SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.
Dey Pharma, L.P., a subsidiary of Mylan Inc., today launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use.
The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and well over 282,000 deaths. A new study published on the preprint server bioRxiv in May 2020 suggests that the long-term impact of the virus could include activation of dormant bacterial infections like tuberculosis (TB).
Motor vehicle crashes rank as the leading cause of teen deaths and in 2008, 16% of all distraction-related fatal automobile crashes involved drivers under 20 years of age.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 18 |
| Patient months included in arterial venous fistula and catheter summaries | 123 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 61 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 9 |
News Archive
A team of scientists from the University of California, Los Angeles, USA, recently conducted a survey investigating the association between availability of testing facilities and COVID-19-related behavioral aspects. Their findings reveal that testing unavailability independently influences certain COVID-19-related behaviors that may increase the risk of SARS-CoV-2 transmission.
SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.
Dey Pharma, L.P., a subsidiary of Mylan Inc., today launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use.
The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and well over 282,000 deaths. A new study published on the preprint server bioRxiv in May 2020 suggests that the long-term impact of the virus could include activation of dormant bacterial infections like tuberculosis (TB).
Motor vehicle crashes rank as the leading cause of teen deaths and in 2008, 16% of all distraction-related fatal automobile crashes involved drivers under 20 years of age.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 14 |
| Hospitalization Rate in facility | 217.2 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 593.3 |
| Hospitalization Rate: Lower Confidence Limit | 86.1 |
News Archive
A team of scientists from the University of California, Los Angeles, USA, recently conducted a survey investigating the association between availability of testing facilities and COVID-19-related behavioral aspects. Their findings reveal that testing unavailability independently influences certain COVID-19-related behaviors that may increase the risk of SARS-CoV-2 transmission.
SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.
Dey Pharma, L.P., a subsidiary of Mylan Inc., today launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use.
The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and well over 282,000 deaths. A new study published on the preprint server bioRxiv in May 2020 suggests that the long-term impact of the virus could include activation of dormant bacterial infections like tuberculosis (TB).
Motor vehicle crashes rank as the leading cause of teen deaths and in 2008, 16% of all distraction-related fatal automobile crashes involved drivers under 20 years of age.
› Verified 6 days ago
The rate of readmission show you whether patients who were being treated regularly at American Fork Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 29.9 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 48.2 |
| Readmission Rate: Lower Confidence Limit | 14.9 |
News Archive
A team of scientists from the University of California, Los Angeles, USA, recently conducted a survey investigating the association between availability of testing facilities and COVID-19-related behavioral aspects. Their findings reveal that testing unavailability independently influences certain COVID-19-related behaviors that may increase the risk of SARS-CoV-2 transmission.
SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.
Dey Pharma, L.P., a subsidiary of Mylan Inc., today launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use.
The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has thrown much of the world into disarray, with over 4 million people reported infected and well over 282,000 deaths. A new study published on the preprint server bioRxiv in May 2020 suggests that the long-term impact of the virus could include activation of dormant bacterial infections like tuberculosis (TB).
Motor vehicle crashes rank as the leading cause of teen deaths and in 2008, 16% of all distraction-related fatal automobile crashes involved drivers under 20 years of age.
› Verified 6 days ago